Resolvins, protectins and maresins are individual families of specialized pro-resolving mediators biosynthesized from the dietary n-3 polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid. These enzymatically oxygenated polyunsaturated lipid mediators were first elucidated during the resolution phase of acute inflammation in animal models of selflimited inflammation. Specialized pro-resolving mediators display potent bioactions when administrated in vivo. Biosynthetic pathway studies have revealed that individual lipoxygenases and cyclooxygenase-2 converts eicosapentaenoic acid and docosahexaenoic acid into distinct families of the resolvins, protectins and maresins. Recently n-3 docosapentaenoic acid was found to be a substrate for the biosynthesis of several novel families of specialized pro-resolving mediators. One example is PD1 n-3 DPA . During the 6th European Workshop on Lipid Mediators, Frankfurt, Germany, the structural elucidation, total organic synthesis, studies on the biosynthetic pathway, as well as the potent anti-inflammatory and pro-resolving properties of PD1 n-3 DPA were presented. Herein, we provide an overview of these topics for the new member PD1 n-3 DPA of the super-family of pro-resolving mediators.
are abundant in marine organisms and fish oil commercial products that are widely used as dietary supplements [1] . These essential fatty acids have long been associated with potential beneficial roles in human health and in the prevention of various diseases [2, 3] , immunomodulation [4] , autoimmune diseases [5] , rheumatoid arthritis [6] , cardiovascular diseases [7] , Alzheimer's disease [8] , type-2 diabetes [8] , and certain cancers [9] . The omega-3 PUFAs EPA and DHA have for a long time believed to possess anti-inflammatory properties [10, 11] by competing with arachidonic acid (AA), resulting in a reduction of the biosynthesis of pro-inflammatory eicosanoids derived from AA [11] . Examples of eicosanoids are the prostaglandins, thromboxanes and leukotrienes [12] . However, the detailed molecular mechanisms and cellular events behind the aforementioned competition are still unclear. Recent efforts have shown that resolving inflammatory exudates use EPA and DHA to produce distinct families of oxygenated PUFA products [13] . The resolvins [14, 15] , protectins [15] [16] [17] and maresins [18] , as well as the recently described sulfido-conjugates RCTRs (resolvin conjugates in tissue regeneration), PCTRs (protectin conjugates in tissue regeneration), and MCTRs (maresin conjugates in tissue regeneration [19] [20] [21] , are examples of distinct families of PUFA derivatives coined specialized pro-resolving lipid mediators (SPMs) [22] . Both DHA and EPA are substrates for the lipoxygenase (LOXs) enzymes as well as cyclooxygenase-2 (COX-2) ( [22] . The biosynthetic conversion of the omega-3 PUFAs EPA and DHA into SPMs is of particular interest towards elucidating the many health benefits attributed to supplementing these PUFAs in the diet [22] . Recent efforts have provided the first detailed molecular mechanistic insights in endogenous anti-inflammatory and pro-resolution actions of the SPMs that may, at least in part, explain the beneficial health effects of EPA and DHA, disease and aging associated with excessive inflammation [22] . Moreover, intake of the non-steroidal anti-inflammatory drug aspirin together with omega-3 supplement has also been reported to be an advantage for human health [23] . Notably, in the presence of aspirin and COX-2, metabolically more stable R-epimers of some SPMs are formed [24] .
SPMs are agonists towards GPCRs resulting in potent anti-inflammatory and proresolving bioactions
The SPMs play essential roles in the return to homeostasis or a normal physiological state [25] .
The molecular, biochemical and cellular events involved in the return to homeostasis have been coined catabasis [26] . The SPMs display potent nanomolar agonist effects in vivo [27] and act as ligands for individual G-protein coupled receptors (GPCRs) [28] . The activation of one or several GPCRs induces cellular functions that explain the bioactivities of the SPMs [27, 28] . At current time, it is unclear whether other DHA-derived SPMs participate in GPCR signaling [28] .
The molecular identification of the GPCRs that protectin D1 (PD1) or PD1 n-3 DPA elicit signaling responses has not yet been fully characterized, nonetheless initial studies on protectin D1 have shown cell-type specific activity that was structure dependent, lending support for at least one receptor [29] . This was also supported by using radiolabelled protectin D1, showing that there is specific binding to leukocytes [29] . In Table 1 , an overview of the receptors that SPMs act on is provided. SPMs display potent anti-inflammatory and pro-resolving bioactions that are key events in the promotion of the termination of ongoing inflammation. In this setting, SPMs also limit further neutrophil recruitment to the inflammatory sites, accelerate the resolution time in vivo and increase the clearance of bacteria and apoptotic cells. For a review on the cellular events involved in resolution of acute inflammation and recently introduced signs of resolution of inflammation, see reference [25] . These bioactions have attracted a considerable interest in the biomedical and health care communities as efforts on n-3 PUFA supplementation and lead compounds for the development of new drugs against many human diseases [25] . The most studied SPMs of the DHA class are protectin D1 (PD1), maresin 1 (MaR1), resolvin D1 (RvD1) and resolvin D2 (RvD2) [22] , see Fig. 2 for chemical structures. biosynthesized from DHA, and the novel SPM PD1 n-3 DPA biosynthesized from n-3 DPA.
More recent findings have disclosed that SPMs protect the host from bacterial infections [30] and govern tissue regeneration, as reviewed by Serhan and co-workers [22] . In addition, protectin D1 also display potent neuroprotective effects in neuronal systems [17] , and is sometimes referred to as (neuro)protectin D1. Some SPMs have entered clinical trial development programs [27] .
n-3 Docosapentaenoic acid (n-3 DPA) is also a substrate and precursor for SPM formation
It has been shown that the all-Z PUFA n-3 docosapentaenoic acid (n-3 DPA, 22:5, n-3)
participates in several fundamental cellular processes and is an intermediate in the metabolic pathway of DHA [31] . The first double bond in n-3 DPA is at C7 while in DHA the first double bond is at C4, see Figure 1 . These differences give rise to different biophysical properties resulting in different functional and biological roles of n-3 DPA and DHA, for example in neuronal systems [32] . The PUFA n-3 DPA is part of our normal diet through fish and lean red meat [33] . In recent years, studies have shown that intake of n-3 DPA provides potential beneficial health effects, which include anti-inflammatory actions, antiplatelet aggregation, and improved plasma lipid profile [32] . Moreover, an enhancement in circulating levels of n-3 DPA is followed by a simultaneous decrease in the level of DHA due to single nucleotide polymorphisms observed in the gene encoding for the fatty acid elongase 2 (ELOVL2) enzyme [34] . It has also been reported that the biosynthesis of thromboxane A 2 (TxA 2 ) [35] and prostacyclin [36] was reported altered by n-3 DPA in platelets. In addition, 11-and 14-hydroxydocosapentaenoic acid metabolites [35] are also produced in platelets from this PUFA.
Previously, the synthesis of chemically pure n-3 DPA was achieved [37] .
The biological observations mentioned spurred an interest in investigating if n-3 DPA is enzymatically converted during inflammation-resolution processes in mice and by human macrophages. Towards such aims, Dalli, Colas and Serhan reported in 2013 the isolation, structural elucidation and biological evaluations of several novel SPMs biosynthesized from n-3 DPA [38] . Herein, a review of the structural elucidation, the total organic synthesis and the identified biosynthetic pathway of one of these novel SPMs, namely PD1 n-3 DPA is provided [38, 39] . In addition, the potent in vivo anti-inflammatory and pro-resolving properties are also presented.
Results and discussion

Structural elucidation using LC/MS-MS and matching experiments with material obtained from total synthesis
SPMs are formed in pico-to nanogram amounts in vivo. To obtain the complete configuration assignment of PD1 n-3 DPA , a stereoselective total synthesis was needed. The key steps in the total synthesis are two highly Z-selective Lindlar reductions of internal alkynes, a stereocontrolled Evans-acetate aldol reaction with Nagao's chiral auxiliary, a Wittig reaction and the use of a chiral pool derived glycidol-ether. The chirality of the alcohols at C10 and C17 as well as the double bond geometry of the triene were assured using these synthetic protocols, see reference [39] for details.
In order to determine whether synthetic prepared material matched the endogenous PD1 n-3 DPA , authentic SPM material from murine self-resolving exudates as well as human macrophages was (Fig. 2) .
Identical UV spectra for both synthetic and endogenously produced PD1 n-3 DPA were also observed with  max MeOH 262, 271 and 282 nm, as expected for a E,E,Z-triene [25] providing further evidence matching the physical properties of the synthetic material with endogenous PD1 n-3 DPA .
Biosynthetic studies of PD1 n-3 DPA
The LOXs belongs to a family of non-heme iron-containing dioxygenases that catalyze the insertion of molecular oxygen into PUFAs containing one or more Z,Z-1,4-pentadiene moieties is most likely S [42] .
Fig. 3.
Biosynthetic pathway for PD1 n-3 DPA . For details on the individual enzymatic steps in the biosynthesis of oxygenated PUFAs, the readers should consult reference [24] and [41] .
The identification of methanol trapping products renders support for involvement of an epoxide intermediate in the biosynthesis of PD1 n-3 DPA
Experiments designed to probe the tentative biosynthetic pathway outlined in Fig. 3 were then performed. The results from these experiments support the proposed pathway [39] . Soybean lipoxygenase-15 (50 U/100 mL) was incubated with n-3 DPA (0.2 µM in 200 µL) in borate buffer (pH = 8.2) at ambient temperature. To this excess acidified MeOH (pH ~3.5) was added in order to quench the enzymatic activity, but also to promote opening of any epoxide intermediate. [39] . These efforts allowed the structural assignment of four methyl-ether products, see Fig. 4 . Therefore, a similar biosynthetic pathway with the involvement of a 16S,17S-epoxide derived from n-3 DPA should be anticipated. However, final proof would be to perform a stereoselective synthesis of 16S,17S-PD n-3 DPA epoxide and then subject this synthetic material to biosynthetic studies.
Epoxide intermediates are also involved in the biosynthesis of other lipid mediators
Epoxides have also been reported earlier as intermediates in the biosynthesis of oxygenated PUFAs, including lipid mediators derived from EPA and DHA [47, 48] 
Biological evaluations
To obtain further evidence for the complete structure of PD1 n-3 DPA it was essential to assess that the synthetic material carried the potent biological actions described for PD1 n-3 DPA .
Administration of synthetic material using 10 ng per mouse significantly reduced neutrophil recruitment during peritonitis, following zymosan A challenge, as determined by light microscopy and flow cytometry. These bioactions were comparable to those displayed by the DHA derived SPM protectin D1. Human macrophage phagocytosis, macrophage efferocytosis and the clearance of apoptotic neutrophils are all key processes in the resolution of inflammation.
Altogether, such actions are defining for a true SPM. Therefore the abilities of synthetic material of PD1 n-3 DPA to stimulate human macrophage phagocytosis and efferocytosis were investigated.
Incubation of synthetic material with human macrophages with increasing concentrations of synthetic material of PD1 n-3 DPA gave rise to an increase in macrophage phagocytosis of both fluorescence labeled yeast cell wall particles (zymosan A) as well as apoptotic neutrophils.
Similar effects were also observed for protectin D1. In addition, PD1 n-3 DPA potently, at concentrations in the pico-to nanomolar range, increased macrophage efferocytosis of apoptotic human neutrophils, a key pro-resolving biological action. The trend towards a bell-shaped doseresponse curve with these isolated human cells was seen. Overall, these results verified that PD1 n-3 DPA exhibited both potent anti-inflammatory and pro-resolving actions, confirming the potent immunoresolvent properties of this SPM, but also established the complete structure of this novel mediator as (7Z,10R,11E,13E,15Z,17S,19Z)-10,17-dihydroxydocosa-7,11,13,15,19-pentaenoic acid.
Summary
Herein the new evidence recently obtained on the structure-function of the growing numbers of the endogenously formed specialized pro-resolving mediator super-family is provided for a novel member, namely PD1 n-3 DPA . The distinct families of SPMs are chemically characterized by two or three chiral, secondary alcohols, separated by either an E,E,Z-triene or an E,Z,E,E-tetraene moiety. As of today, structural elucidation of these oxygenated PUFA derivatives using LC-MS/MS based metabololipidomics is necessary along with derivatives to deduce endogenous structures of the bioactive products [56] , since only pico-to nanogram amounts of biosynthetic material are formed. Matching with synthetic material obtained by stereoselective total synthesis is essential for the exact configuration assignment of SPMs, but also for thorough biological evaluations.
Resolution of inflammation is now held to be an active process where SPMs playing an important role in maintaining homeostasis. Studies in humans are contributing new knowledge that supplementation with n-3 PUFAs is increasing the biosynthesis of SPMs [47, 48, 57] .
Further biological studies of the n-3 DPA derived SPMs continue to be of interest [58] .
The different families of SPMs display high structural complexity due to the presence of several stereogenic centers, both in the form of chiral, secondary alcohols and conjugated E-and Zdouble bonds [24] , reflecting their biochemical origins, functions and stereospecific bioactions towards individual GPCRs [27] . Hence, acquired knowledge and distinct care must be exercised when working with SPMs. Failure of such diligent operations will not reveal the correct chemical structures or the exciting bioactions that SPMs possesses as resolution agonists.
Elucidating the role of PUFAs and their oxygenated products at the cellular and molecular level in health is of current interest [23] , [47, 48] , [58] . The SPMs are among the most exciting small molecules currently under investigations towards drug development and elucidating the biology of resolution of inflammation [59] . Only prudent handling of each SPM, due to their delicate chemical structures, will be met with success within this interesting field of biomedical research.
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